Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis RL Levine, M Wadleigh, J Cools, BL Ebert, G Wernig, BJP Huntly, ... Cancer cell 7 (4), 387-397, 2005 | 3869 | 2005 |
MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia Y Pikman, BH Lee, T Mercher, E McDowell, BL Ebert, M Gozo, A Cuker, ... PLoS medicine 3 (7), e270, 2006 | 1798 | 2006 |
Expression of Jak2V617F causes a polycythemia vera–like disease with associated myelofibrosis in a murine bone marrow transplant model G Wernig, T Mercher, R Okabe, RL Levine, BH Lee, DG Gilliland Blood 107 (11), 4274-4281, 2006 | 613 | 2006 |
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera G Wernig, MG Kharas, R Okabe, SA Moore, DS Leeman, DE Cullen, ... Cancer cell 13 (4), 311-320, 2008 | 458 | 2008 |
Mapping the pairwise choices leading from pluripotency to human bone, heart, and other mesoderm cell types KM Loh, A Chen, PW Koh, TZ Deng, R Sinha, JM Tsai, AA Barkal, ... Cell 166 (2), 451-467, 2016 | 448 | 2016 |
Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells A Mullally, SW Lane, B Ball, C Megerdichian, R Okabe, F Al-Shahrour, ... Cancer cell 17 (6), 584-596, 2010 | 413 | 2010 |
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation X Lu, R Levine, W Tong, G Wernig, Y Pikman, S Zarnegar, DG Gilliland, ... Proceedings of the National Academy of Sciences 102 (52), 18962-18967, 2005 | 376 | 2005 |
Preventing Engrailed-1 activation in fibroblasts yields wound regeneration without scarring S Mascharak, HE DesJardins-Park, MF Davitt, M Griffin, MR Borrelli, ... Science 372 (6540), eaba2374, 2021 | 352 | 2021 |
Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells D Kim, J Wang, SB Willingham, R Martin, G Wernig, IL Weissman Leukemia 26 (12), 2538-2545, 2012 | 256 | 2012 |
Unifying mechanism for different fibrotic diseases G Wernig, SY Chen, L Cui, C Van Neste, JM Tsai, N Kambham, H Vogel, ... Proceedings of the National Academy of Sciences 114 (18), 4757-4762, 2017 | 204 | 2017 |
Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands I Moraga, G Wernig, S Wilmes, V Gryshkova, CP Richter, WJ Hong, ... Cell 160 (6), 1196-1208, 2015 | 165 | 2015 |
The Jak2 V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes G Wernig, JR Gonneville, BJ Crowley, MS Rodrigues, MM Reddy, ... Blood, The Journal of the American Society of Hematology 111 (7), 3751-3759, 2008 | 165 | 2008 |
Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation A Czechowicz, R Palchaudhuri, A Scheck, YU Hu, J Hoggatt, B Saez, ... Nature communications 10 (1), 617, 2019 | 158 | 2019 |
JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow … T Mercher, G Wernig, SA Moore, RL Levine, TL Gu, S Fröhling, D Cullen, ... Blood 108 (8), 2770-2779, 2006 | 141 | 2006 |
Integrated spatial multiomics reveals fibroblast fate during tissue repair DS Foster, M Januszyk, KE Yost, MS Chinta, GS Gulati, AT Nguyen, ... Proceedings of the National Academy of Sciences 118 (41), e2110025118, 2021 | 113 | 2021 |
Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders RL Levine, G Wernig ASH Education Program Book 2006 (1), 233-239, 2006 | 112 | 2006 |
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia MM Loriaux, RL Levine, JW Tyner, S Fröhling, C Scholl, EP Stoffregen, ... Blood, The Journal of the American Society of Hematology 111 (9), 4788-4796, 2008 | 108 | 2008 |
Activation of JUN in fibroblasts promotes pro-fibrotic programme and modulates protective immunity L Cui, SY Chen, T Lerbs, JW Lee, P Domizi, S Gordon, Y Kim, G Nolan, ... Nature Communications 11 (1), 2795, 2020 | 87 | 2020 |
Surgical adhesions in mice are derived from mesothelial cells and can be targeted by antibodies against mesothelial markers JM Tsai, R Sinha, J Seita, N Fernhoff, S Christ, T Koopmans, GW Krampitz, ... Science translational medicine 10 (469), eaan6735, 2018 | 82 | 2018 |
Elucidating the fundamental fibrotic processes driving abdominal adhesion formation DS Foster, CD Marshall, GS Gulati, MS Chinta, A Nguyen, A Salhotra, ... Nature communications 11 (1), 4061, 2020 | 66 | 2020 |